• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

March 15, 2020
Company Drug/Device Medical Condition Status
Debiopharm Debio 0123 refractory solid tumors that have recurred or progressed following prior platinum-based chemotherapy and for which no standard treatment is available initiation of phase 1 trial
FSD Pharma Ultra Micro-Plmitolylethanolamide (PEA) inflammatory conditions initiation of phase 1 trial
Virometix V-306 vaccine respiratory syncytial virus initiation of phase 1 trial
Actinium Pharma Actimab-A CLAG-M combination relapsed or refractory acute myeloid leukemia first patient treated in third and final cohort of phase 1 trial
Innate Pharma

AstraZeneca
IPH5201 alone and in combination with durvalumab with or without oleclumab advanced solid tumors first patient dosed in phase 1 trial
Medivir AB MIV-818 advanced liver cancer first patient dosed in phase 1b study
InMed Pharma INM-755 epidermolysis bullosa and potentially other dermatological diseases patient enrollment complete in phase 1 study
Albireo elobixibat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease patient enrollment complete in phase 2 study
Tenax Therapeutics levosimendan pulmonary hypertension and heart failure with preserved ejection fraction patient enrollment complete in phase 2 study
Palvella Therapeutics PTX-022 (QTORIN 3.9% rapamycin anhydrous gel) Pachyonychia Congenita patient enrollment complete in phase 2/3 study
QED Therapeutics infigratinib adjuvant treatment of invasive urothelial carcinoma first patient dosed in phase 3 trial
ARVOBIO AVR-RD-04 gene therapy cystinosis Orphan Drug designation granted by FDA
TG Therapeutics umbralisib follicular lymphoma Orphan Drug designation granted by FDA
Spero Therapeutics oral SPR720 nontuberculous mycobacterial infection Orphan Drug designation granted by FDA
Janssen JNJ-6372 metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy Breakthrough Therapy designation granted by FDA
Neuronetics NeuroStar Advanced Therapy System bipolar depression Breakthrough Device designation granted by FDA
Aerin Medical RhinAer Stylus chronic rhinitis approved by the FDA
Allergan Durysta (bimatoprost implant) open-angle glaucoma or ocular hypertension approved by the FDA
AltaThera Pharmaceuticals Sotalol IV atrial fibrillation new indications approved by the FDA
Boehringer-Ingelheim Ofev (nintedanib) chronic fibrosing interstitial lung diseases with a progressive phenotype approved by the FDA
Bristol-Myers Squibb Opdivo (nivolumab) and Yervoy (ipilimumab) hepatocellular carcinoma which has been previously treated with Bayer’s Nexavar (sorafenib) approved by the FDA
Recordati Isturisa (osilodrostat) Cushing's disease when pituitary surgery is not an option or has not been curative approved by the FDA

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing